Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors

https://doi.org/10.1016/S0960-0760(96)00225-7Get rights and content

Abstract

Two potent non-steroidal inhibitors (CB7645 and CB7661) of human cytochrome P45017α were tested for in vivo activity in WHT mice. There were no signs of toxicity, but there was no effect on the androgen-dependent organs. The pharmacokinetics and biochemistry of the compounds in mice were investigated. Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 μM, respectively, occurred after 2–4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h. CB7645 produced some decrease in plasma testosterone at 4 h, but this was not sustained. When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with Ki values of 10 and 13 nM, respectively. However, the Km for the substrate progesterone was lower at 4.3 nM. These data indicate that, for effective and continuous inhibition of the murine cytochrome P45017α enzyme, higher peak levels of the compounds would be required, and these levels would need to be maintained throughout the treatment period.

References (14)

There are more references available in the full text version of this article.

Cited by (34)

  • Castration-resistant prostate cancer: From new pathophysiology to new treatment

    2014, European Urology
    Citation Excerpt :

    This leads to a secondary rise in adrenocorticotropic hormone and excess mineralocorticoids. To prevent this, AA is coadministered with prednisone 5 mg twice daily [8–10]. In phase 1 and 2 studies there were no dose-limiting toxicities (DLTs) associated with AA, and the main side effects were hypokalemia and lower-limb edema (due to excess mineralocorticoids).

  • The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer

    2013, Cancer Drug Design and Discovery: Second Edition
  • New treatment options for patients with metastatic castration-resistant prostate cancer

    2012, Cancer Treatment Reviews
    Citation Excerpt :

    The combination of cabazitaxel and prednisone has been approved by health authorities around the world, including the European Union, Canada, South Korea, and many countries in South America and approval is pending in numerous other countries. Abiraterone is an oral agent that inhibits cytochrome P450 (CYP) 17, thus blocking androgen production in the testes, prostate, and adrenal glands.22–24 In October 2010, the interim results of the global Phase III trial (COU-AA-301) in patients who had received prior docetaxel were reported at the European Society for Medical Oncology meeting and were later published.

  • At the crossroads of steroid hormone biosynthesis: The role, substrate specificity and evolutionary development of CYP17

    2011, Biochimica et Biophysica Acta - Proteins and Proteomics
    Citation Excerpt :

    The novel CYP17A1 inhibitor, abiraterone acetate (a pregnenolone-derived compound), was developed as a mechanism-based steroidal inhibitor. The features that set it apart from the other candidates are the 3-pyridyl substituent and a double bond between positions C16 and C17 of the steroidal skeleton (these result in both potency and selectivity), which makes this compound a good CYP17A1 inhibitor (Kiapp of < 1 nM) [42,43]. Investigation of mechanisms of action of CYP17A1 inhibitors is an important task not only for anticancer drug discovery but also for screening of compounds with endocrine disrupting activities.

View all citing articles on Scopus
View full text